FairJourney, which is headquartered in Portugal, will be further capitalised by Partners Group, alongside GHO and FairJourney founder and CEO, António Parada.

Under GHO’s ownership FairJourney Biologics has become an established leader in antibody discovery and development, with more than 5x revenue growth since 2019. Reed Smith also advised GHO on its initial investment in FairJourney in 2020, and on FairJourney’s subsequent add-on acquisition of Iontas, which added patented innovative antibody discovery technology and further R&D labs in Cambridge, UK.

The Reed Smith team advising on the sale was led by corporate partner Sam Webster, supported by tax partner Gareth Amdor, corporate associates James Hatchard, Victoria Bryden, Georgia Moorhouse and Alexander Pierce, tax associate Alia Khalil, and specialist lawyers across the firm’s life sciences, regulatory, competition, intellectual property, data privacy, finance, employment, real estate, and environmental practices.